Intravenous immunoglobulin bridging to rituximab in NMDAR encephalitis patients non-responders to first-line treatments.

Federico MassaDiego FranciottaStefano GrisantiLuca RoccatagliataSilvia MorbelliSabrina BeltraminiAntonio UccelliAngelo SchenoneLuana Benedetti

Published in: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2022)

Our observations suggest that the herein-described protocol might be used in patients with NMDAR encephalitis at risk for poor prognosis in the mid-term when they need to shift to rituximab. [18F]-FDG-PET confirmed to be a sensitive tool to detect the minimal brain lesions that can underlie isolated cognitive and psychiatric symptoms.

Keyphrases

poor prognosis
long non coding rna
diffuse large b cell lymphoma
end stage renal disease
pet ct
ejection fraction
newly diagnosed
positron emission tomography
pet imaging
prognostic factors
mental health
hodgkin lymphoma
high dose
chronic lymphocytic leukemia
physical activity
depressive symptoms
patient reported